Personal (Official) Website

Prof. Chinedum Peace Babalola


  • Follow Facebook
  • Follow on Twitter
  • Follow on YouTube

Publications

LIST OF PUBLICATIONS (IN CHRONOLOGICAL ORDER)

 

 

Articles in Journals

 1

Zheng Y, Walsh T, Gulsuner S, Casadei S, Lee MK, Ogundiran TO, Ademola A, Falusi AG, Adebamowo CA, Oluwasola AO, Adeoye A, Odetunde A, Babalola CP, Ojengbede OA, Odedina S, Anetor I, Wang S, Huo D, Yoshimatsu TF, Zhang J, Felix GES, King M,  Olopade OI (2018) “Inherited Breast Cancer in Nigerian Women’. Journal of Clinical Oncology 36(28):2820-2825. [USA] doi/full/10.1200/JCO.2018.78.3977

 2

Nwogu JN, Kotila OA, Obaro M, Babalola CP (2018) Effects of antacids on the pharmacokinetics and electrocardiographic dynamics of Lumefantrine In healthy volunteers. African Journal of Medicine and Medical Sciences 47:161-169 [Nigeria-Pubmed] 

 3

Akinjo RO, Chinaka CN, Babalola CP (2018) “The effects of surfactant and storage conditions on the in-vitro release of quinine suppository made from witepsol base” Nigerian Journal of Pharmaceutical Research. 14 (1): 53-59  (Nigeria) ISSN 0189-8434

 4

Odeniran, OA, Obiageri O. Obodozie-Ofoegbu OO, Nwogu JN, Babalola CP (2018) Effect of fixed-dose sizes on in vitro properties of artemether-lumefantrine tablets. Journal of Pharmacy and Bioresources, 15 (2) 188-196.

 5

Pitt JJ, Riester M, Zheng Y, Yoshimatsu TF, Sanni A, Oluwasola O, Veloso A, Labrot E, Wang S, Odetunde A, Ademola A, Okedere B, Mahan S, Leary R, Macomber M, Ajani M, Johnson RS, Fitzgerald D, Grundstad AJ, Tuteja JH, Khramtsova G, Zhang J, Sveen E, Hwang B, Clayton W, Nkwodimmah C, Famooto B, Obasi E, Aderoju V, Oludara M, Omodele F, Akinyele O, Adeoye A, Ogundiran T, Babalola C, MacIsaac K, Popoola A, Morrissey MP, Chen LS, Wang J, Olopade CO, Falusi AG, Winckler W, Haase K, Van Loo P, Obafunwa J, Papoutsakis D, Ojengbede O, Weber B, Ibrahim N, White KP, Huo D, Olopade OI, Barretina J. (2018). Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features. Nature Communication 9(1):4181. doi: 10.1038/s41467-018-06616-0. Erratum in: Nature Communication. 2019 Jan 14;10(1):288. [USA]

 6

Okeke IN, Babalola CP, Byarugaba DK, Djimde A, Osoniyi OR (2017) “Broadening Participation in the Sciences within and from Africa: Purpose, Challenges, and Prospects” CBE—Life Sciences Education 16:es2. DOI:10.1187/cbe.15-12-0265

 7

Adejumo OE, Kotila TR , Falusi AG, Silva BO, Nwogu JN, Fasinu PS, Babalola CP (2016) Phenotyping and genotyping of CYP2C19 using comparative metabolism of proguanil in sickle-cell disease patients and healthy controls in Nigeria. Pharmacology Research & Perspectives, 4(5): e00252. doi:  10.1002/prp2.252

 8

Nwogu J., Ma Q., Babalola CP, Adedeji W., Morse G., and Taiwo B. (2016) Pharmacokinetic, Pharmacogenetic and other factors influencing CNS penetration of antiretrovirals. AIDS Research and Treatment doi:  10.1155/2016/2587094

 9

Falade OB, Falusi AG, Olaniyi AA, Ezeasor C, Kwasi D, and Babalola CP (2016) Significant Pharmacokinetic Interactions Between Quinine and Ampicillin–Cloxacillin Combination. Drugs in R&D 16:193–203  DOI 10.1007/s40268-016-0128-x

 10

Akpan RM, Kotila AO, Akpa MO, Fawole O, Falusi GA, Babalola CP (2015) Self-reported sulphonamide hypersensitivity reactions in adults living in Ibadan, Nigeria: Across-sectional, community-based study. Nigerian Medical Journal 56(6): 404-410. doi:  10.4103/0300-1652.171611

 11

OI Olopade, A Odetunde, M Riester, T Yoshimatsu, E Labrot, A Ademola, A Sanni, B Okedere, S Mahan, I Nwosu, R Leary, M Ajani, RS Johnson, E Sveen, Y Zheng, W Clayton, G Khramtsova, M Oludara, F Omodele, O Benson, A Adeoye,O Morhason-Bello, T Ogundiran, C Babalola, A Popoola, M Morrissey, D Huo, A Falusi, W Winckler, J Obafunwa, D Papoutsakis, O Ojengbede, N Ibrahim,O Oluwasola, and J Barretina (2015) Genomic landscape of breast cancers from women of African    ancestry across the diaspora. Cancer Research 76(4 Supplement): DOI: 10.1158/1538-7445.

 12

Adegoke OA, Babalola CP, Obuebhor O. (2014) Simultaneous spectrophotometric determination of trimethorprim and sulphamethoxazole following charge-transfer complexation with chloranilic acid. Arabian Journal of Chemistry http//dx.doi.org/10.1016/j.arabjc.2014.05.022

 13

Babalola CP, Kolade YT, Adeyemo MA, Kotila OA, Ameh SJ, Adelakun TA, Adewuyi S, Scriba GK (2014). Effect of Caffeine-Containing Beverages on Physicochemical and Release Properties of Halofantrine. Global Journal of Medical Research: B Pharma, Drug Discovery, Toxicology and Medicine. 14(1): 5-10

 14

Babalola CP, Oluwalana I, Kotila OA, Adegoke OA, Kolade YT, Ameh SJ (2014) ‘A Novel Derivatization Ultraviolet Spectrophotometric Method for the Determination of Dihydroartemisinin Using P-Nitroaniline’ Tropical Journal of Pharmaceutical Research 13(1):127-133. http://dx.doi.org/10.4314/tjpr.v13i1.18

 15

Arowolo AO, Njiaju UO, Ogundiran TO,Abidoye O, Lawal OO, Obajimi M, Adetiloye AV,Im HK, Akinkuolie AA, Oluwasola A, Adelusola K, Kayode AA, Agbakwuru AE, Oduntan H, Babalola CP, Fleming G, Olopade OC, Falusi AG, Durosinmi MA and Olopade OI (2013) ‘Neo-adjuvant Capecitabine Chemotherapy in Women with Newly Diagnosed Locally Advanced Breast Cancer in a Resource-poor Setting (Nigeria): Efficacy and Safety in a Phase II Feasibility Study’. The Breast Journal, 19(5):470-477,  DOI: 10.1111/tbj.12149’

 16

Kotila O.A, Olaniyi O, Adegoke O.A, Babalola C.P. (2013). Experimental Determination of the Physicochemical Properties of Lumefantrine. African Journal of Medicine and Medical Sciences, 42:209-214

 17

Babalola CP, Kanu DN, Okafor  GO,  Wumi A, Ajayi O, Kotila OA,  Farombi EO. (2013). Toxicological Effect of SubTherapeutic, Therapeutic andOverdose regimens of Halofantrine Hydrochloride on Male Albino Rats. Pharmacologia 4 (3): 180-185

 18

Babalola CP, Oguntuase F, Ademowo G, Ameh S (2012). Effect of caffeine co-administration with halofantrine and other antimalarials on parasite clearance in Plasmodium berghei infected mice. Pharmacie Globale International Journal of Comprehensive Pharmacy (IJCP), 01 (02) (Available online at www.pharmacie-globale.info)

 

 19

Babalola CP, Ajayi O, Kotila O, Ameh S (2012). In-Vitro Interaction Studies of Lumefantrine with Antacids. Pharmacie Globale International Journal of Comprehensive Pharmacy (IJCP), 01 (05) (Available as online open access at www.pharmacie-globale.info)

 20

Ameh SJ, Obodozie OO, Chindo BA, Babalola CP, Gamaniel KS (2012). Herbal Clinical Trials-Historical Development and application in the 21st century. Pharmacologia; 3(5):121-131.

 21

Ameh SJ, Obodozie OO, Babalola CP, Gamaniel KS (2011) Medical Herbalism and Clinical Research: A global Perspective. British Journal of Pharmaceutical Research; 1(4): 99-123

 22

Babalola CP, Awoleye SA, Akinyemi JO, Kotila OA (2011) Evaluation of prescription pattern in Osun State (Southwest) Nigeria. Journal of Public Health & Epidemiology, 3(3): 94-98

 23

Babalola CP, Kotila OA, Dixon PAF, Oyewo EE (2011) Disposition of quinine and its major metabolism 3-hydroxyquinine in patients with liver diseases. Research in Pharmaceutical Biotechnology, 3(3): 25-29

 24

Adegoke O.A., Babalola CP, Isaac P.O.K., Kotila O.A (2011): ‘Spectrophotometric studies of the charge-transfer complexation between Lumenfantrine and chloranilic acid’ Acta Pharmaceutica Scientia 53:135-149 (Turkey].

 25

CDI group: Amazigo U, …Babalola CP et al (2010) ‘Community-Directed interventions for priority health problems in Africa: results of a multicountry study’ Bulletin of World Health Organisations  88(7):509-518 [Switzerland] doi: 10.2471/BLT.09.069203

 26

Babalola, CP, Adejumo O., Din U., Zhiheng X., Odetunde A., Kotila T., Falusi A.G., Nagar S. (2010): ‘Cytochrome P450 CYP2C19 genotypes in sickle cell disease patients and normal controls’. Journal of Clinical Pharmacy and Therapeutics. 35:471-477 [UK].

 27

Babalola CP, Olori EO, Kotila OA, Falade O, Kolade YT, Sylva BO (2009): Effect of Artesunate on the Urinary Excretion of Cloaxillin in Healthy Subjects”. Nigerian Journal of Pharmaceutical Research 7(1):29-36 (Nigeria)

 28

Babalola CP, Kolade YT, Olaniyi AA, Adedapo A, Scriba GKE (2009): Effect of fluconazole on the pharmacokinetics of halofantrine in healthy volunteers. Journal of Clinical Pharmacy and Therapeutics. 34:677-682 [UK].

 29

Babalola CP (2008): Ethics in Pharmacy Practice. The Nigerian Journal of Pharmacy 41:30-36 [Nigeria].

 30

Babalola CP (2008) Regulatory Bodies and Monitoring Clinical Trials. In Strengthening the Capacity of Research Ethics Committees in Africa, © 2008 ISBN 978-978-083-544-6 University of Ibadan, Nigeria; Pp 52-60.

 31

Kolade YT, Babalola CP, Olaniyi AA, Scriba GK (2008) Effect of kolanut on the pharmacokinetics of the antimalarial drug halofantrine. European Journal of Clinical Pharmacology 64(1):77-81 [Germany].

 32

Kolade YT, Adegbolagun OM, Idowu SO, Babalola CP, Olaniyi AA (2006): Comparative determination of halofantrine by titrimetry, spectrophotometry and liquid chromatography.   African Journal Medicine and Medical Sciences 35 (1):79-84 [Nigeria]

 33

Kolade YT, Babalola CP, Scriba GKE (2006): Analysis of the antimalarial drug halofantrine and its major metabolite N-desbutylhalofantrine in human plasma by high performance liquid chromatography. Journal of Pharmaceutical and Biomedical Analysis 41(1) 315-319 [UK].

 34

Adegoke OA, Babalola CP, Oshitade OS, Famuyiwa AA (2006): Determination of the physicochemical properties of pyronaridine – a new antimalarial drug. Pakistan Journal of Pharmaceutical Sciences 19(1):1-5 [Pakistan].

 35

Sowunmi A, Fateye BA, Adedeji AA, Fehintola FA, Bamgboye EA, Babalola CP, Happi TC, Gbotosho GO, (2005): Effects of antifolates – co-trimoxazole and pyrimethamine-sulfadoxine – on gametocytes in children with acute, symptomatic, uncomplicated, Plasmodium falciparum malaria. Memorias do Instituto Oswaldo Cruz. 100(4):451-455 [Brazil].

 36

Ong CT, Babalola CP, Nightingale CH, Nicolau DP (2005): Penetration, intracellular accumulation and efflux of tigecycline in human polymorphonuclear neutrophils (PMNs).  Journal of Antimicrobial Chemotherapy  56:498-501 [UK].

 37

Maglio D, Banevicius MA, Sutherland C, Babalola C, Nightingale CH, Nicolau DP (2005): Pharmacodynamic profile of ertapenem against Klebsiella pneumonia and Escherichia coli in a murine thigh model. Antimicrobial Agents and Chemotherapy 49(1):276-280 [USA].

 38

Sowunmi A, Adedeji AA, Babalola CP (2005): Randomised comparison of cardiac effects of halofantrine and chloroquine plus chlorpheniramine in children with acute falciparum malaria using a novel method: Disposition kinetics of the relative increase in electrocardiograph time intervals (DISKRIETI). Journal of Applied Therapeutic Research. 5(4): 41-48 [UK].

 39

Babalola CP, Adebayo AS, Omotosho A, Ayinde O (2004): Comparative bioavailability study of a new quinine suppository and oral quinine in healthy volunteers. Tropical Journal of Pharmaceutical Research. 3(1): 291-297 [Nigeria].

 40

Babalola CP, Nightingale CH, Nicolau DP (2004): Effect of adjunctive treatment with interferon against Pseudomonas aeruginosa in neutropenic and non-neutropenic hosts.  International Journal of Antimicrobial Agents24(3):219-225 [UK].

 41

Babalola CP, Nightingale CH, Nicolau DP (2004): Adjunctive efficacy of G-CSF on treatment of Pseudomonas aeruginosa pneumonia in neutropenic and non-neutropenic hosts. Journal of Antimicrobial Chemotherapy 53(6):1098-1100 [UK]. DOI: 10.1093/jac/dkh237

 42

Adedeji AA, Babalola CP, Sowunmi A (2004): Clinical characteristics and kinetic indices of resistant Plasmodium falciparum during treatment with chloroquine in Nigerian children. Journal of Applied Therapeutic Research 5(2):37-44. [UK].

43 

Babalola CP, Bolaji OO, Ogunbona FA, Ezeomah E (2004): Absolute bioavailability of quinine formulations in Africa. African Journal Medicine and Medical Sciences 33(3):185-189 [Nigeria].

 44

Sowunmi A, Adedeji AA, Fateye BA, Babalola CP (2004): Plasmodium falciparum hyperparasitaemia in children: Risk factors, treatment outcomes and gametocytaemia following treatment. Parasite 11(3):317-323 [France].

 45

Babalola CP, Oladimeji FA, Femi-Oyewo M (2004): Pharmacokinetics and saliva secretion of paracetamol in healthy adult Nigerians” West African Journal of Medicine23(1):10-14 [Nigeria].

 46

Babalola CP, Patel KB, Nightingale CH, Nicolau DP (2004): Synergistic activity of vancomycin and teicoplanin alone and in combination with streptomycin against Enterococci faecalis with various vancomycin susceptibilities. International Journal of Antimicrobial Agents 23: 343-348 [UK].

 47

Babalola CP, Adegoke O, Ogunjimi MA, Osimosu MO (2003): Determination of Physicochemical Properties of Halofantrine. African Journal of Medicine and Medical Sciences32(4):357-359 [Nigeria].

 48

Babalola CP, Fashedemi TT, Olaniyi AA (2003): Chloroquine reduces urinary excretion of cloxacillin when it is administered concurrently with ampicillin-cloxacillin combination. Tropical Journal of Pharmaceutical Research, 2(1): 169-173 [Nigeria]

 49

Babalola CP, Scriba GKE, Sowunmi A, Alawode OA (2003): Liquid chromatographic determination of pyronaridine in human plasma and oral dosage form. Journal of Chromatography B 792 (2): 265-272 [Netherlands].

 50

Adejumo OE, Oseni OB, Babalola CP, Kotila TR, Olaniyi AA  (2002): Proguanil versus pyrimethamine in long short term malaria chemoprophylaxis in sickle cell disease and pregnancy. Nigerian Journal of Pharmaceutical Research 1: 22-25 [Nigeria].

 51

Babalola CP, Iwheye GB, Olaniyi AA (2002): Effect of proguanil interaction on bioavailability of cloxacillin. Journal of Clinical Pharmacy and Therapeutics, 27: 461-464 [UK]

 52

Bolaji OO, Sadare IO, Babalola CP, Ogunbona FA (2002): Polymorphic oxidative metabolism of proguanil in a Nigerian population. European Journal of Clinical Pharmacology, 58:543-545 [Germany]. DOI 10.1007/s00228-002-0509-7

 53

Babalola CP, Oladimeji FA, Femi-Oyewo M (2001): Correlation between in vitro and in vivo parameters of commercial paracetamol tablets. African Journal of Medicine and Medical Sciences, 30:275-280 [Nigeria].

 54

Babalola CP, Ola SO, Olaniyi AA, Otegbayo JA, Fakeye TO (2001): Comparative physicochemical and clinical trials of two commercial non-sedimenting magnesium antacids in patients with acid peptic disease. The Nigerian Journal of Pharmacy, 32:38-44 [Nigeria].

 55

Onyeji CO, Adebayo AS, Babalola CP (1999): Effects of absorption enhancers in chloroquine suppository formulations: In vitro release characteristics. European Journal of Pharmaceutical Sciences, 9: 131-136 [Netherlands].

 56

Babalola CP, Oyewo EA, Bolaji OO, Dixon PAF (1998): Quinine pharmacokinetics and toxicity in Nigerian subjects. West African Journal of Pharmacology and Drug Research, 14: 1-5 [Nigeria].

 57

Babalola CP, Bolaji OO, Ogunbona FA, Sowunmi A, Walker O (1998): Pharmacokinetics of quinine in African patients with falciparum malaria. Pharmacy World and Science (Now International Journal of Clinical Pharmacy), 20: 118-122 [Netherlands]. doi:10.1023/A:1008699022244

 58

Babalola CP, Bolaji OO, Ogunbona FA, Sowunmi A, Walker O (1997): Dose linearity of quinine in healthy human subjects. European Journal of Pharmaceutics and Biopharmaceutics, 44: 143-147 [Netherlands].

 59

Babalola CP, Bolaji OO, Ogunbona FA, Dixon PAF (1996): Relationship between plasma and saliva quinine levels in humans. Therapeutic Drug Monitoring, 18: 30 – 33 [USA].

 60

Onyeji CO, Babalola CP (1993): The effects of magnesium trisilicate on proguanil absorption. International Journal of Pharmaceutics, 100: 249 – 252 [Netherlands].

 61

Babalola CP, Bolaji OO, Dixon PAF, Ogunbona FA (1993): Column liquid chromatographic analysis of quinine in human plasma, saliva, and urine. Journal of Chromatography, 616: 151 – 154. ERRATUM (1999): Journal of Chromatography B Vol. 731, 419 [Netherlands]. doi:10.1016/0378-4347(93)80482-J

 62

Bolaji OO, Babalola CP, Dixon PAF (1991): Characterization of the major metabolite of quinine in human urine by H – NMR spectroscopy. Xenobiotica, 21 (4): 447 – 450 [UK]. DOI:

10.3109/00498259109039484

 63

Komolafe OO, Anyabuike C P, Obaseki AO (1988): The possible role of mixed–function oxidases in the hepatobiliary toxicity of Azadirachta indica. Fitoterapia, 59 (2): 109 – 113 [Italy].

 64

Obaseki AO, Adeyi O, Anyabuike CP (1985): Some serum enzymes levels as marks of possible acute effects of aqueous extract of Azadirachta indica on membranes in vivoFitoterapia, 56 (2): 111 – 115 [Italy].

 

 

Books, Monographs and Chapters in Books

 1

Babalola CP & Durowaiye MA (Editors) (2016) – ‘Proceedings of International Conference on Medicine Regulation of Claims- From Concept to Launch’ organized by Centre for Drug Discovery Development and Production (CDDDP), University of Ibadan in conjunction with Reckitt Benckiser, UK supported by MacArthur Grant Foundation held at University of Ibadan, Nigeria, 2 - 4 December, 2013. © 2013 ISBN 978-978-54726-1-5 Ibadan, Nigeria. 132pp. www.cdddp.ui.edu.ng

 2

Babalola CP (2013) Anticounterfeit Research on Panadol and Panadol Extra in Nigeria. A Technical Report to GSK Pharma Limited, Nigeria

 3

Babalola CP (2011) Drugs and Mankind: A display of Uniqueness. University of Ibadan Inaugural Lecture 2010/2011 series. © Ibadan University Press, 2011. ISBN: 978-978-8414-55-1

 4

Adeniyi, Joshua D.; Soyibo, Doyin; Bankole, A.S.; Adeniyi, Bolanle A.; Babalola, Chinedum P.; Osho, J.A.; Ayede, A.I.; Ndekwu, O.S. and Osowole, O.S.(2008) (part report) Community – Directed Interventions for major health problems in Africa: A multi country study final WHO report: DOI 10.2471/tdr.07

 5

Falusi, AG, Ajuwon, AJ, Obajimi, M, Babalola, CP and Obono O (Editors) (2005): Guidelines For Ethical Reviews; University of Ibadan & University College Hospital Institutional Review Committee (UI/UCH IRC): © ISBN 978-36756-8-0 University of Ibadan, Nigeria.

 6

Babalola, CP (2005): Drugs and Mankind. In: Oguntomisin, GO and Edo, VO (Editors): African Culture And Civilization – A Textbook For GES 102 © ISBN 978-069-960 General Studies Programme (GSP), University of Ibadan, Nigeria; Pp136-152.

 7

Babalola, CP and Idowu O.S. (2005): Drugs and Mankind. In: K.O. Okonjo and A.T. Bolarinwa (Editors): Science, Industry and Mankind – A Textbook For GES 104 © ISBN 978-068-745-9 General Studies Programme (GSP), University of Ibadan, Nigeria; Pp39-54.

 8

Olaniyi, AA, Babalola, CP, Oladeinde, FO and Adegoke OA (Editors). (2001): Towards Better Quality Assurance of Drugs in the 3rd Millennium – Biopharmaceutical Methods in Drug Quality Assurance. © 2001 ISBN 978-30585-6-8 Ibadan, Nigeria

 9

Babalola, CP and Jaiyeoba, K.T. (2001): Multisource drug products and interchangeability. In: Olaniyi, AA, Babalola, CP, Oladeinde, FO and Adegoke, O (Editors). Towards Better Quality Assurance of Drugs in the 3rd Millennium – Biopharmaceutical Methods in Drug Quality Assurance. © 2001 ISBN 978-30585-6-8 Ibadan, Nigeria; Pp 100-114.

 10

Babalola, CP (2001): Bioavailability/Bioequivalence (BA/BE) assessment. In: Olaniyi, AA, Babalola, CP, Oladeinde, FO and Adegoke, OA (Editors). Towards Better Quality Assurance of Drugs in the 3rd Millennium – Biopharmaceutical Methods in Drug Quality Assurance. © 2001 ISBN 978-30585-6-8 Ibadan, Nigeria; Pp 79-99.

 11

Babalola, CP and Olaniyi, AA (1998): Case reports on counterfeit and substandard active pharmaceutical ingredients and medicinal products In: Olaniyi, AA and Idowu, SO (Editors). Detection and Identification of Counterfeit and Substandard Pharmaceutical Products. © 1998 ISBN 978-30585-3-3 Ibadan, Nigeria; Pp50-56.

 

 

Published Abstracts:

1.

D.A. Kwasi, C.P. Babalola, I.C. Uzochukwu, O.O. Olubiyi and I.N. Okeke (2019).  Pathogen Box Screen Identifies Novel Enteroaggregative Escherichia coli (EAEC) Biofilm Inhibitors. Abstract Accepted for ASM Microbe 2019, June 20-24 2019 at San Francisco, California USA. (accepted)

2.

D.A. Kwasi, C.P. Babalola, I.C. Uzochukwu, O.O. Olubiyi and I.N. Okeke (2019). Workshop and short presentation at Wellcome Trust Course (WGC ACSC) on Practical Aspects of Small Molecule Drug Discovery - Cape Town, South Africa 7 - 12 April 2019. (accepted)

3.

D.A. Kwasi, C.P. Babalola, I.C. Uzochukwu and I.N. Okeke (2018). Pathogen Box Screen Uncovers Novel Enteroaggregative Escherichia coli (EAEC) Antiadhesins. Abstract and Oral presentation at Drug Discovery and Pathogen Box Conference and Workshop from 4th-6th July 2018 held at Faculty of Pharmaceutical Sciences, Nnamdi Azikiwe University, Awka.

4.

D.A. Kwasi, C.P. Babalola, I.C. Uzochukwu and I.N. Okeke (2017) Identifying Lead Antiadhesin Against Enteroaggregative Escherichia coli (EAEC) Causing Diarrhoea in Children. Oral presentation at Grand Challenge Africa Sentinel Meeting organized by Alliance for Excellence in Sciences in Africa (AESA) on 10th August 2017 at Radisson Blu Lusaka, Zambia. Among the selected 20 across Africa (2 from Nigeria), We addressed the Research Community 2017 BMGF Discovery Leadership team on "Identifying Lead Antiadhesin Against Enteroaggregative. Escherichia coli (EAEC) Causing Diarrhoea in Children".

5.

Jason J. Pitt, Toshio F. Yoshimatsu, Yonglan Zheng, Jason Grundstad, Jigyasa Tuteja, Jiebiao Wang, Abayomi Odetunde, Galina Khramtsova, Wendy Clayton, Adeyinka Ademola, Temidayo O. Ogundiran, Adenike T. Adeniji-Sofoluwe, Millicent Obajimi, Adewunmi Adeoye, Chinedum Babalola, Oladosu A. Ojengbede, Christopher O. Olopade, Oluwasola A. Olayiwola, Lin Chen, Dezheng Huo, Kevin P. White, Olufunmilayo I. Olopade (2016). Whole genome sequencing reveals different patterns of mutational mechanisms in breast tumors between women of African and European descent. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4494. http://cancerres.aacrjournals.org/content/76/14_Supplement/4494; DOI: 10.1158/1538-7445.AM2016-4494

6

Labrot E….Babalola C… et al (2016) Unveiling the African Breast Cancer Genome: The West Africa Breast Cancer Study (WABCS) DOI: 10.13140/RG.2.1.4366.2321

7

Babalola CP, Kwasi D, Ayede IA.  Effect of antimalarials on Pharmacokinetics of Ceftriaxone in Neonates and Children Suffering from Malaria and Bacteria Infections In South West Nigeria. 75th FIP World Congress of Pharmacy and Pharmaceutical Sciences 2015, Düsseldorf, Germany, 29 September – 3 October, 2015. Abstract No.: FIPSUB-1217

8

Kotila OA, Akpa MO, Fawole O. Falusi AG. Babalola CP. N-acetyltransferase II enzyme haplotyping in HIV-positive and healthy Nigerians and its relatedness to sulphonamide hypersensitivity. Nigeria Association of Pharmacists in Academia (NAPA) Annual National Conference & Scientific Meeting at University of Ibadan, Nigeria 10-14 August 2015. Book of Abstract pp73.

9

Nwogu JN, Kotila OA, Michael O. Babalola CP. Effects of antacids on the pharmacokinetic and electrocardiographic pharmacodynamics of Lumefantrine in healthy Nigerian volunteers. Nigeria Association of Pharmacists in Academia (NAPA) Annual National Conference & Scientific Meeting at University of Ibadan, Nigeria 10-14 August 2015. Book of Abstract pp44

10

Adejumo O, Babalola CP, Falusi AG, Nagar SV, Kotila T Phenotype-Genotype Analysis of CYP2C19 in Sickle Cell Disease Patients and Non-Sickle Cell Volunteers in Nigeria 19th North American ISSX Meeting / 29th JSSX Meeting. Hilton San Francisco, San Francisco, California, USA. October 19 - 23, 2014.

11

Falade O.B, Babalola C.P. Pharmacokinetic and Pharmacodynamic Interactions between Ampicillin-Cloxacillin Combination and Quinine. 5th Annual Conference of Universities on Global Health (CUGH), Washington D.C, USA, 10th-12th May, 2014. Abstract No. 815

12

Babalola C.P, Dibie E., Adeyemo J. Perception of Drug Analysis by Key Players in Pharmaceutical Industry and Distribution. 26th Annual General Meeting and Scientific Symposium of the West African Postgraduate college of Pharmacists, Accra, Ghana. 10th-12th March, 2014.

13.

Kotila O.A, Fawole O, Ayede A.I, Olopade O.I, Falusi A.G, Babalola C.P. NAT2 haplotype distribution in a Nigerian population. 5th FIP Pharmaceutical Sciences World Congress 2014, Melbourne, Australia, 13th – 16th April, 2014, Abstract No. PF-027.

14

Akpan M.R, Kotila O.A, Akpa O.M, Ayede A.I, Fawole O., Olopade O.I, Falusi A.G, Babalola C.P. Self-reported adverse reactions to sulphonamides in Ibadan, Oyo State, Nigeria. 86th National Conference of the Pharmaceutical Society of Nigeria, 4th – 8th November, 2013.

15

Olayinka A. Kotila, Chinedum P. Babalola, Olufunmilayo Fawole, Adeyinka G.Falusi, Soma Das, Olufunmilayo I. Olopade (2012) ‘Genotype analysis of NAT2 gene in HIV-positive Nigerians’. Third Unibadan Biomedical Conference, University of Ibadan; 2012

16

Babalola C.P.; Akpan M.; Kotila O.; Falusi A.G.; Fawole O.; (2011) Prevalence of sulphonamides adverse reactions in HIV positive patients attending PEPFAR clinic, University College Hospital, Ibadan, South West, Nigeria’ African Organisation for Research and Training in Cancer (AORTIC) Conference, Egypt. November-December, 2011

17

Babalola C.P.and Ajayi O.M. (2010) ‘In vitro interaction studies between lumefantrine and antacids’ In Proceedings of Second Unibadan Conference on Biomedical Research, University of Ibadan, Nigeria; 6-9 July, 2010

18

Babalola C.P., Olaniyi A.A., Iwheye G.B., Fashedemi T.T., Ajoku C.E. , Adeniyi B.A., Falade O.and Olori E.O. (2010) ‘Significant interactions between some antibiotics and antimalarial drugs’ In Proceedings of Second Unibadan Conference on Biomedical Research, University of Ibadan, Nigeria; 6-9 July, 2010

19

Falusi A.G., Ajuwon A.J. Babalola C.P. (2009) ‘The outcome of an Intervention on capacity Development of Ethics Review Committee in Nigeria’ African Organisation for Research and Training in Cancer (AORTIC) Conference; Tanzania 10-15 November, 2009

20

Babalola C.P., O. Adejumo, U. Din, X. Zhiheng, A. Odetunde, T. Kotila, A.G. Falusi, S. Nagar (2009). “Cytochrome P450 CYP2C19 Genotypes in Sickle Cell Disease Patients and Normal Controls in an African Population” In Proceedings of 16th North American Regional Meeting of ISSX in Maryland, USA on October 18 – 22, 2009. Abstract# 322

21

Babalola C.P., I.O. Falana, Y. Kolade 2009) “Novel derivative ultraviolet spectrophotometric method for the determination of dihydroartemisinin” In Proceedings of 11th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology (IATDMCT), Montréal, Québec, Canada. October 3-8, 2009.

22

Babalola C.P., D. N. Kanu, G. O. Okafor (2008) “Toxic Effect of Sub-Therapeutic and Therapeutic Doses of Halofantrine on Albino Rats” In Proceedings of 15th North American Meeting of ISSX in San Diego, California , USA on October 12 – 16, 2008. Abstract # 248

23

Babalola C.P., A. Olaniyi, G. Iwheye., T. Fashedemi., C. Ajoku, B. Adeniyi (2008)

 ‘Significant Drug-Drug Interactions between classical antibiotics and antimalaria drugs’ Paul Ehrlich II World Conference on Magic Bullet taking place in Nurnberg, Germany from October 3-5, 2008.

24.

Babalola C. P. and E.O Olori (2008) ‘Effect of artesunate on the urinary excretion of cloxacillin after co-administration of ampicillin-cloxacillin combination with artesunate in healthy subjects’ In Proceedings of Annual Conference & Scientific Meeting of Nigerian Association of Pharmacists in Academia (NAPA), Obafemi Awolowo University, Ile-Ife; 30th July-2nd Aug., 2008, Page 28.

25.

Babalola C. P. and O. J. Adegbola (2008) ‘Drug-Drug interactions between amoxicillin and dihydroaertemisinin’. In Proceedings of Annual Conference & Scientific Meeting of Nigerian Association of Pharmacists in Academia (NAPA), Obafemi Awolowo University, Ile-Ife; 30th July-2nd Aug., 2008, Page 24.

26

Babalola C.P., Kolade Y.T., Scriba G.K.E., Olaniyi A.A., Adedapo A. (2007) Effect of fluconazole on the pharmacokinetics of halofantrine in healthy volunteers” 10th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology (IATDMCT), Nice, France. 2007. Abstract# 32

27

Babalola C.P., Olaniyi A.A., Iwheye G.B., Fashedemi T.T., Ajoku C.E., Adeniyi B.A. (2006) Drug-drug interaction studies between beta lactam antibiotics and some classical antimalarials. Dental Association Scientific Conference, University of Ibadan, Nigeria. 2006

28

Babalola C.P., Dixon P.A.F., Oyewo E.A. (2005) “Disposition of quinine and its major metabolite, 3-hydroxy quinine in patients with liver disease” 13th North American ISSX/20th JSSX Meeting, October 23-27, 2005 Maui, Hawaii, USA, Abstract #132.

29

Babalola C.P., Kolade Y., Omoruyi S, Onyeji C.O. (2005) “Liquid determination of halofantrine and its principal metabolite desbutyl halofantrine in human plasma” Therapeutic Drug Monitoring 27(2):#212. 9th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, Louisville, Kentucky, USA April 23-28, 2005.

30

Kolade Y., Babalola C.P., Olaniyi A. and Scriba G.K.E. (2004) ‘Effect of Kolanut (a caffeine-containing nut) on the solubility and pharmacokinetics of the antimalaria drug, halofantrine. National Conference of the Pharmaceutical Society of Nigeria (PSN) held at Owerri in November, 2004.

31

Ong C. T., Babalola C. P., Nightingale C. H. and Nicolau D. P (2004). “Penetration, intracellular accumulation and efflux of tigecycline in human polymorphonuclear neutrophils (PMNs)” In Proceedings of Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Conference. September, 2004, USA.

32

Maglio D., Banevicius M. A., Sutherland C., Babalola C., Nightingale C. H. and Nicolau D. P. (2004) “Pharmacodynamic profile of ertapenem against Klebsiella pneumonia and Escherichia coli in a murine thigh model” In Proceedings of Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Conference. September, 2004, USA.

33

Babalola C.P., Ajoku C.E. & Adeniyi B.A. (2004) In vitro drug-drug interaction between ampicillin and chloroquine. Drug Metabolism Reviews [online] Available at: http://pharm.u.i.edu.ng and https://library.villanova.edu (Accessed 10 October, 2010) (abstract).

34

Babalola C., Nightingale C. H. and Nicolau D. P. (2003) “Influence of G-CSF on treatment of Pseudomonas aeruginosa pneumonia in non-neutropenic host”. In Proceedings of American College of Clinical Pharmacy (ACCP) Annual Conference, November 2-5, 2003; Atlanta, Georgia.

35

Babalola C. P., Oyeyinka A. and Omotosho A.  (2001) “Comparative bioavailability of a new quinine suppository in healthy subjects”. In Proceedings of 7th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology, Washington DC USA September 1-6, 2001.

36

Babalola C. P., Itiola O. A. and Adisa R. (1999) “Formulation of quinine from suppositories: Effects of polyethylene glycol” In proceedings of MIM African Conference in conjunction with Southern African Malaria Project and Roll Back Malaria Project of the World Health Organisation, Durban, South Africa, 14th – 19th March, 1999, ppC21-C22.

37

Babalola C. P. (1999) “The relevance of quinine in current treatment of malaria: The African experience” In proceedings of Third World Organisation for Women in Science (TWOWS) Second General Assembly International Conference, Cape Town, South Africa.

38

Bolaji O. O., Omogbenigun I., Babalola C. P. and Ogunbona F. A. (1997) “Oxidative polymorphism of proguanil in an African population” In proceedings of the 5th Congress of Therapeutic Drug Monitoring and Clinical Toxicity, Vancouver, Canada.

39

Babalola C. P., Bolaji O. O., Ogunbona F. A., Sowunmi A. and Walker O. (1996) “Dose proportionality of quinine following oral administration of 250 – 1000 mg doses of quinine to healthy volunteers” In Proceedings of 7th North American International Society for the Study of Xenobiotics (ISSX) Meeting, San Diego, U. S. A.

40

Babalola C. P., Bolaji O. O., Ogunbona F. A. and Sowunmi A. (1992). “The bioavailability of some quinine formulations.”In proceedings of the Second Jerusalem Conference on Pharmaceutical Sciences and Clinical Pharmacology, Jerusalem, Israel. Abstract Page 22.

41

Babalola C. P., Bolaji O. O. and Dixon P. A. F.  (1991). “Pharmacokinetics of quinine in healthy Nigerians.” In proceedings of International Pharmaceutical Federation. 51st Congress of Pharmaceutical Sciences, Washington, DC, U. S. A. Page Cs 138.

42

Babalola C. P. and Dixon P. A. F.  (1991). “Liquid chromatographic analysis of quinine in human plasma.” In proceedings of International Pharmaceutical Federation. 51st Congress of Pharmaceutical Sciences, Washington, DC, U. S. A. Page Cs 115

43

Babalola C. P., Bolaji O. O. and Dixon P. A. F.   (1990). “Pharmacokinetics of quinine in healthy Nigerian subjects” In proceedings of Scientific Session of the Pharmaceutical Society of Nigeria, Lagos, Nigeria. Page 50.


 

Copyright © 2021. All Rights Reserved.
Prof. Chinedum Peace Babalola » «


Designed By CLETCOM
Photo Gallery